Onyx Biotec LimitedONYXCorporate

Latest results: Mar 2026 6 quarters of data

—

MCap —

Live price not available

Onyx Biotec Limited — Stock analysis & AI research Onyx Biotec Limited — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹35 Cr

Sales · Mar 2026

+9.7% YoY

₹2 Cr

Operating Profit · Mar 2026

-47.1% YoY

7.0%

OPM % · Mar 2026

-52.1% YoY

₹1 Cr

Net Profit · Mar 2026

-65.0% YoY

₹0.38

EPS · Mar 2026

-65.1% YoY

📝 Onyx Biotec Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Onyx Biotec Limited reported revenue of ₹35 crore for the quarter ended March 2026 (Q4 FY26), up 9.7% from ₹32 crore in the same quarter last year.

Net profit fell 65.0% year-on-year to ₹1 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹0.38.

Operating profit stood at ₹2 crore — an operating margin (OPM) of 7.0%, compared with 14.6% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹69 crore with a net loss of ₹0 crore.

Shareholding pattern

As of Mar 2026, promoters held 65.10%, foreign institutional investors (FIIs) 1.07%, domestic institutional investors (DIIs) 2.39%, public shareholders 31.44% of Onyx Biotec Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

N/A

Current Price ?

N/A

P/E ?

N/A

Industry P/E ?

N/A

P/B ?

N/A

P/S ?

N/A

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹69 Cr

OPM ?

4.9%

Profit after tax (TTM) ?

₹-0 Cr

EPS (TTM) ?

₹-0.12

ROCE ?

1.1%

ROE ?

-0.4%

ROA ?

-0.2%

Growth

Sales — latest qtr ?

₹35 Cr

PAT — latest qtr ?

₹1 Cr

YoY qtr sales growth ?

9.7%

YoY qtr profit growth ?

-65.0%

Sales growth (3y) ?

21%

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹15 Cr

Debt to Equity ?

0.27

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

65.10%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

N/A

Return 6 months ?

N/A

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	24	30	30	32	35	35	+9.7%	—
Operating Profit	3	5	6	5	1	2	-47.1%	—
Other Income	0	0	1	0	0	0	+16.7%	—
Interest	1	1	1	1	1	1	+6.5%	—
Depreciation	1	1	2	2	2	1	-1.3%	—
Profit Before Tax	2	3	4	3	-1	1	-81.0%	—
Net Profit	2	2	3	2	-1	1	-65.0%	—
EPS	2.71	1.52	2.24	1.09	-0.50	0.38	-65.1%	—
OPM %	14.3%	16.4%	18.9%	14.6%	2.7%	7.0%	-52.1%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	5.90	13.32	18.13	18.13	+0.0%
Reserves	12.30	11.97	37.49	37.28	-0.6%
Borrowings	29.23	30.78	12.46	15.17	+21.7%
Other Liabilities	11.30	18.07	23.17	24.57	+6.0%
Total Liabilities	58.73	74.14	91.25	95.15	+4.3%
Fixed Assets	42.50	43.48	40.90	39.16	-4.3%
CWIP	0.00	0.00	0.00	3.68	—
Investments	0.00	0.00	0.00	0.00	—
Other Assets	16.23	30.66	50.35	52.31	+3.9%
Total Assets	58.73	74.14	91.25	95.15	+4.3%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	1.96	1.52	1.42	-1.49	-204.9%
Cash from Investing Activity	-22.68	-3.15	0.66	-4.58	-793.9%
Cash from Financing Activity	16.43	3.09	5.07	1.50	-70.4%
Net Cash Flow	-4.30	1.46	7.15	-4.57	-163.9%
Free Cash Flow	-20.78	-1.70	1.91	-6.48	-439.3%
CFO/OP	44%	18%	14%	-44%	-414.3%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	46.95	104.37	119.19	144.49	+21.2%
Inventory Days	109.92	92.94	150.14	99.20	-33.9%
Days Payable	120.16	140.83	156.02	124.70	-20.1%
Cash Conversion Cycle	36.71	56.48	113.32	118.98	+5.0%
Working Capital Days	-52.22	37.62	87.49	77.29	-11.7%
ROCE %	8.23%	12.85%	12.16%	1.14%	-90.6%

👥 Shareholding (latest 4 periods)

Metric	Nov 2024	Mar 2025	Sep 2025	Mar 2026	% Chg
Promoters	65.10%	65.10%	65.10%	65.10%	+0.0%
FIIs	8.72%	5.36%	1.95%	1.07%	-45.1%
DIIs	3.29%	2.39%	2.39%	2.39%	+0.0%
Public	22.89%	27.15%	30.56%	31.44%	+2.9%
No. of Shareholders	1,181	551	640	586	-8.4%

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.

❓ Frequently asked questions

What was Onyx Biotec Limited's revenue in Q4 FY26?